Nestlé is providing $40.7m to Paris-based biopharmaceutical company Enterome for an R&D project targeting food allergies and inflammatory bowel disease, hrough its Nestlé Health Science division.
Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition.
You’ll be able to unsubscribe at any time.